Biohaven Interest Expense
Interest Expense of Biohaven (BHVN) as of Oct 21, 2026.
Get this data via API
Financial Data API
Interest Expense
0.00USD
Last updated:
Interest Expense of Biohaven is 2023 0.00 USD. Interest Expense of Biohaven was 2022 0.00 USD. It decreases by % lower compared to the previous year.
The Biohaven Interest Expense history
3 Years
10 Years
25 Years
Max
Interest Expense
Date
Interest Expense
Jan 1, 2016
-2.96 M USD
Jan 1, 2017
-18.60 M USD
Jan 1, 2018
-15.75 M USD
Jan 1, 2019
-49.24 M USD
Jan 1, 2020
-4.16 M USD
Jan 1, 2021
5.26 M USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
| YEAR | Interest Expense | YoY |
|---|---|---|
| 0.00USD | — | |
| 0.00USD | -100.00% | |
| 5.26 MUSD | -226.44% | |
| -4.16 MUSD | -91.55% | |
| -49.24 MUSD | +212.63% | |
| -15.75 MUSD | -15.32% | |
| -18.60 MUSD | +528.38% | |
| -2.96 MUSD | — | |
| 0.00USD | — | |
| 0.00USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Biohaven Stock analysis
What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Biohaven stock
On Eulerpool you can find the complete historical development of Interest Expense Biohaven since 2006 – with annual values, charts, and detailed analysis.
Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.
Interest Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Biohaven historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Biohaven
All Key Metrics — Biohaven
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth